Emcure Pharmaceuticals' Credit Ratings Reaffirmed by CARE Ratings; Long-term Facilities at CARE AA; Stable
CARE Ratings reaffirmed Emcure Pharmaceuticals' credit ratings. Long-term bank facilities are rated CARE AA; Stable, and short-term facilities are rated CARE A1+. The company reported FY26 revenue of ₹9,322 crore, up 18% YoY, with a PBILDT margin of 20.0%. Emcure also acquired full ownership of Gennova Biopharmaceuticals.
Credit rating reaffirmations are important for a company's borrowing costs and investor confidence. While not a direct financial event like results, it impacts the company's ability to access capital at favorable terms.
The credit ratings have been reaffirmed at stable levels, indicating continued financial strength and positive business outlook. The company's revenue growth and improved profitability further support a positive sentiment.
Emcure Pharmaceuticals Limited announced that CARE Ratings Limited has reaffirmed its credit ratings for the company's bank facilities. The long-term bank facilities, enhanced from ₹557.50 crore to ₹785.00 crore, have been reaffirmed at CARE AA with a Stable outlook. Additionally, long-term/short-term bank facilities totaling ₹1,563.00 crore (enhanced from ₹1,348.00 crore) were reaffirmed at CARE AA; Stable / CARE A1+, and short-term bank facilities of ₹52.00 crore were reaffirmed at CARE A1+.
The reaffirmation by CARE Ratings factors in Emcure's healthy business risk profile, diversified revenue base, leadership in key therapeutic segments, accredited manufacturing facilities, experienced management, and strong R&D capabilities. The company reported revenue of approximately ₹9,322 crore in FY26, a 18% year-on-year growth, driven by international markets. Profitability also improved, with the PBILDT margin increasing to 20.0% in FY26 from 18.7% in FY25. Emcure also strengthened its portfolio through strategic partnerships and product developments, including an additional 12.05% stake acquisition in Gennova Biopharmaceuticals Limited, making it a wholly owned subsidiary.
However, the ratings are constrained by inherent regulatory risks, exposure to foreign exchange fluctuations, and intense competition. CARE Ratings expects Emcure's liquidity position to remain strong, supported by healthy cash accruals. The stable outlook reflects the company's established track record and diversified product profile.
A plain-language summary of a public exchange filing by Emcure Pharmaceuticals Limited. Read the original for the full detail.